Comprehensive guidelines translate research findings into clinical policy for HIV-infected transplant candidates and recipients

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 23, Issue 6, 2005, Pages 331-334

  Roland, Michelle E ^a,c   Stock, Peter G ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; VIRUS RNA;

CRYPTOSPORIDIOSIS; DISEASE COURSE; EDITORIAL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; LYMPHOCYTE COUNT; OPPORTUNISTIC INFECTION; ORGAN DONOR; ORGAN TRANSPLANTATION; PATIENT SELECTION; PRACTICE GUIDELINE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; T LYMPHOCYTE; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; CASE MANAGEMENT; CONSENSUS DEVELOPMENT; HOSPITAL ADMISSION; IMMUNE DEFICIENCY; LETTER; LIFE EXPECTANCY; LIVING DONOR; RISK; SPAIN; STANDARD; TREATMENT OUTCOME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE MANAGEMENT; CONSENSUS DEVELOPMENT CONFERENCES; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; LIFE EXPECTANCY; LIVING DONORS; ORGAN TRANSPLANTATION; PATIENT SELECTION; PRACTICE GUIDELINES; RISK; SPAIN; TREATMENT OUTCOME; WAITING LISTS;

EID: 22544436114     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13076171     Document Type: Editorial

References (35)

1. Miró JM, Torre-Cisneros J, Moreno A, Tuset M, Quereda C, Laguno M, et al. Documento de consenso GESIDA/GESITRA-SEIMC, SPNS y ONT sobre trasplante de órgano sólido en pacientes infectados por el VIH en España (marzo 2005). Enferm Infecc Microbiol Clin. 2005;23:353-62.
2. Moreno S, Fortún J, Quereda C, Moreno A, Pérez-Elías MJ, Martín-Dávila P, et al. Liver transplantation in HIV-infected recipients. Liver Transpl. 2005;11:76-81.
3. Teicher E, Duclos-Valles J, Azulay D, Castaing D, Bismuth H, Roque-Afonso A, et al. Liver transplantation in HIV-HCV co-infected patients. San Francisco: 11th Conference on Retroviruses and Opportunistic Infections; 2004. [Abstract #828.]
4. Rufi G, Vargas V, Valdivieso A, Miró JM, Salcedo M, Rafecas A, et al, and the Spanish OLT-HIV Working Group. Orthotopic liver transplantation, in 15 HIV-1-infected récipients: Evaluation of Spanish experience in the HAART era (2002-2003). San Francisco: 11th Conference on Retroviruses and Opportunistic Infections; 2004. [Abstract #827.]
5. Vogel M, Effenberger W, Wolff M, Rockstroh JK, Hirner A, Sauerbruch T, et al. Clinical outcome of orthotopic liver transplantation in HIV-infected patients - a report of 4 cases from the Bonn cohort. Eur J Med Res. 2003; 8 Supl 1:71.
6. Stock PG, Roland ME, Carlson L, Preise CE, Roberts JP, Hirose R, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation. 2003;76:370-5.
7. Samuel D, Duclos-Valles JC, Teicher E, Vittecoq D. Liver transplantation in patients with HIV infection. J Hepatol. 2003;39:3-6.
8. Roland ME, Havlir DV. Responding to organ failure in HIV-infected patients. N Engl J Med. 2003;348:2279-81.
9. Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation. 2003;75:425-9.
10. Ragni MV, Belle SH, Im K, Neff G, Roland M, Stock P, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis. 2003;188:1412-20.
11. Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl. 2003;9:239-47.
12. Roland M, Carlson L, Frasseto L, Murphy B, Keller M, Olthoff K, et al. 1-to-3-year outcomes in HIV-infected liver and kidney transplant recipients. Boston: 12th Conference on Retroviruses and Opportunistic Infections; 2005. [Abstract #953.]
13. Vogel MVE, Wasmuth JC, Brackmann H, Goldmann G, Wolff M, Hirner A, et al. Orthotopic liver transplantation in HIV-positive patients: Outcome of 10 patients from the Bonn cohort. Boston: 12th Conference on Retroviruses and Opportunistic Infections; 2005. [Abstract #931.]
14. Abbott KC, Swanson SJ, Agodoa LY, Kimmel PL. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol. 2004;15:1633-9.
15. García F, Plana M, Arnedo M, Brunet M, Castro P, Gil C, et al. Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: A randomized pilot study. J Acquir Immune Defic Syndr. 2004;36:823-30.
16. Rizzardi GP, Lazzarin A, Pantaleo G. Potential role of immune modulation in the effective long-term control of HIV-1 infection. J Biol Regul Homeost Agents. 2002;16:83-90.
17. Rizzardi GP, Harari A, Capiluppi B, Tambussi G, Ellefsen K, Ciuffreda D, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest. 2002;109:681-8.
18. Margolis DM, Kewn S, Coull JJ, Ylisastigui L, Turner D, Wise H, et al. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr. 2002;31:45-9.
19. Sereti I, Lane HC. Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies. Clin Infect Dis. 2001;32:1738-55.
20. Coull JJ, Turner D, Melby T, Betts MR, Lanier R, Margolis DM. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr. 2001;26: 423-34.
21. Rizzardi GP, Vaccarezza M, Capiluppi B, Tambussi G, Lazzarin A, Pantaleo G. Cyclosporin A in combination with HAART in primary HIV-1 infection. J Biol Regul Homeost Agents. 2000;14:79-81.
22. Heredia A, Margolis D, Oldach D, Hazen R, Le N, Redfield R. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. J Acquir Immune Defic Syndr. 1999;22:406-7.
23. Heredia A, Amoroso A, Davis C, Le N, Reardon E, Dominique JK, et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci USA. 2003;100:10411-6.
24. Prachalias AA, Pozniak A, Taylor C, Srinivasan P, Muiesan P, Wendon J, et al. Liver transplantation in adults coinfected with HIV. Transplantation. 2001;72:1684-8.
25. Tolan DJ, Davies MH, Millson CE. Fibrosing cholestatic hepatitis after liver transplantation in a patient with hepatitis C and HIV infection. N Engl J Med. 2001;345:1781.
26. Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.
27. Roland ME, Lo B, Braff J, Stock PG. Key clinical, ethical, and policy ssues in the evaluation of the safety and effectiveness of solid organ transplantation in HIV-infected patients. Arch Intern Med. 2003;163:1773-8.
28. Calabrese LH, Albrecht M, Young J, McCarthy P, Haug M, Jarcho J, et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N Engl J Med. 2003;348:2323-8.
29. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with Human Immunodeficiency Virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Infectious Diseases Society of American. MMWR; 1999. p. 48.
30. Kumar MS, Sierka DR, Damask AM, Fyfe B, McAlack RF, Heifets M, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int. 2005;67:1622-9.
31. Frassetto L, Aggarwal AM, Bucher P, Jacobsen W, Christians U, Benet LZ, et al. Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. Drug Metabol Pharmacokin. 2003;18:114-20.
32. Jain AK, Venkataramanan R, Fridell JA, Gadomski M, Shaw LM, Ragni M, et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl. 2002;8:838-40.
33. Carter JT MM, Carlson LL, Roland ME, Preise CE, Hirose R, Stock PG. Safety and efficacy of thymoglobulin in HIV-positive renal transplant recipients. Seattle: American Transplant Congress; 2005. [Abstract #1537.]
34. DHHS U. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: US Department of Health and Human Services; 2005.
35. CDC. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR. 2001.